Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | blooms syndrome DNA helicase | 0.002 | 0.5498 | 0.5498 |
Treponema pallidum | ATP-dependent DNA helicase | 0.0005 | 0 | 0.5 |
Plasmodium falciparum | ADP-dependent DNA helicase RecQ | 0.0023 | 0.6343 | 1 |
Plasmodium vivax | ADP-dependent DNA helicase RecQ, putative | 0.0017 | 0.4421 | 0.5 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0011 | 0.1921 | 0.4422 |
Brugia malayi | cytoplasmic intermediate filament protein | 0.0017 | 0.443 | 0.3105 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 1 | 1 |
Echinococcus multilocularis | bloom syndrome protein | 0.0026 | 0.7496 | 0.69 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Echinococcus multilocularis | musashi | 0.0033 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.3573 | 0.2045 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.3793 | 0.2316 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 1 | 1 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Echinococcus granulosus | bloom syndrome protein | 0.0026 | 0.7496 | 0.69 |
Echinococcus granulosus | cytoplasmic intermediate filament protein | 0.0016 | 0.3793 | 0.2316 |
Echinococcus multilocularis | cytoplasmic intermediate filament protein | 0.0016 | 0.3793 | 0.2316 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0011 | 0.1921 | 0.4422 |
Trichomonas vaginalis | DNA helicase recq1, putative | 0.0026 | 0.7496 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 1 | 1 |
Trypanosoma brucei | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0014 | 0.3074 | 0.5 |
Giardia lamblia | Sgs1 DNA helicase, putative | 0.0011 | 0.1921 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.3573 | 0.2045 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.5574 | 0.4522 |
Brugia malayi | Bloom's syndrome protein homolog | 0.0026 | 0.7496 | 0.69 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0017 | 0.4345 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.443 | 0.3105 |
Schistosoma mansoni | DNA helicase recq5 | 0.0011 | 0.1921 | 0.1921 |
Schistosoma mansoni | DNA helicase recq1 | 0.0011 | 0.1921 | 0.1921 |
Trichomonas vaginalis | DNA helicase recq, putative | 0.0026 | 0.7496 | 1 |
Trypanosoma cruzi | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0014 | 0.3074 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.978 | 0.9728 |
Echinococcus multilocularis | lamin | 0.0033 | 1 | 1 |
Entamoeba histolytica | recQ family helicase, putative | 0.0014 | 0.3074 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 1 | 1 |
Leishmania major | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0014 | 0.3074 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | RecQ helicase | 0.0026 | 0.7496 | 0.69 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Anticonvulsant dose (functional) | > 80 mg kg-1 | Compound was tested for anticonvulsant activity by measuring its effect on convulsions induced by bicuculline in mice. | ChEMBL. | 7265114 |
Anticonvulsant dose (functional) | > 80 mg kg-1 | Compound was tested for anticonvulsant activity by measuring its effect on convulsions induced by electroshock in mice. | ChEMBL. | 7265114 |
Anticonvulsant dose (functional) | > 160 mg kg-1 | Compound was tested for anticonvulsant activity by measuring its effect on convulsions induced by isoniazide in mice. | ChEMBL. | 7265114 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.